Effect of calcium ionophore Br-X537A on renin synthesis and release in Amphiuma means kidney culture.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J S Pryor.
Explore the source record for details and available documents.
The amplitudes of muscle and nerve action potentials evoked median nerve stimulation were recorded just before and immediately after haemodialysis. These revealed a growht of action potential amplitude during dialysis. It is suggested that some component of the defective peripheral nerve function that inevitably accompanies uraemia is temporarily improved during dialysis.
A double blind trial of bromocriptine in the treatment of 14 patients with the symptoms of benign prostatic hypertrophy is reported. 5 patients did not complete the trial mainly because of side-effects due to an overdosage of bromocriptine. In the remaining 9 patients there was symptomatic improvement in 6, with objective evidence of improvement in 3 patients on flow rate measurements. The possible modes of action of bromocriptine in this condition are discussed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A double-blind trial was performed in 60 women to establish the effectiveness of an ergot alkaloid, 2-Br-alpha-ergocryptine (ergocryptine; CB 154), in suppressing puerperal lactation and to compare it with stilboestrol and a placebo. At the doses selected ergocryptine and stilboestrol were equally effective.
Three patients suffering from non-puerperal galactorrhoea over periods ranging from two months to six years were treated with an ergot alkaloid, 2-Br-alpha-ergocryptine (CB 154). In all three cases the galactorrhoea was terminated. The apparent prolactin antagonism exhibited by this compound is discussed.
Explore the source record for details and available documents.
1. Bio-assay techniques have been used to measure plasma levels of neurohypophysial hormones in man, following either a single injection or a continuous infusion.2. The median half-life of oxytocin after a single injection of 2 u. was 3.2 min (2.0-5.7, 95% confidence limits); this increased significantly (P < 0.01) to 4.8 min (4.4-6.1) when the hormone was infused at a rate of 500 m-u./min. The vasopressins had appreciably longer half-lives. After a single injection of 1 or 1.5 u. 8-lysine vasopressin (LVP), the half-life was 5.7 min (3.6-6.0). Continuous infusions of the hormones at a rate of 120 m-u./min yielded half-lives of 5.5 min (5.0-7.1) for LVP, and 5.6 min (3.9-9.5) for 8-arginine vasopressin (AVP).3. The apparent volumes of distribution of the hormones were all of the order of two thirds the extracellular volume.4. In accordance with its shorter half-life, the clearance of oxytocin was greater than that of the vasopressins (1.5 l./min, compared with 1.0 l./min).5. The antidiuretic potencies of the hormones were studied in over-hydrated subjects, by measuring the rate of urine excretion following an I.V. injection. Duration of antidiuretic action increased in the order: oxytocin, LVP, AVP. A 5:1 mixture of oxytocin and AVP was not as long-lasting as AVP alone. 8.5% (4-22) of an administered dose of AVP was excreted in the urine, and this amount was significantly correlated with urine volume (r = +0.67, P < 0.05).6. Ultrafiltration of human plasma containing exogenous hormones showed that 30% (13-50) of AVP was bound, the degree of binding being independent of concentration over the range used (50-400 mu-u./ml.) In contrast, oxytocin was completely unbound.7. Exogenous oxytocin was more stable than exogenous AVP in human plasma. At 4 degrees C there was no significant loss of oxytocin until 7 days, whereas 20% of AVP was inactivated in 2 days. At 37 degrees C a 20% loss of AVP occurred within 4 hr, and a 50% loss within 24 hr; corresponding times for oxytocin were 24 and 48 hr.
Explore the source record for details and available documents.